BSE · 538965
Concord Drugs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹36 Cr with net profit ₹1 Cr — a 1.46% net margin, versus 1.31% the period before.
Shareholding
As of 2026-06-30
- Promoter45.08%
- Public54.92%
4,597 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.89× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 9.31 percentage points to 45.08% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #70 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,587 Cr | 38.67 | 5.75 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,874 Cr | 214.19 | 3.45 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,561 Cr | 20.54 | 4.12 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,833 Cr | 19.49 | 4.94 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,05,892 Cr | 52.56 | 6.5 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,273 Cr | 88.03 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,378 Cr | 431.21 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,476 Cr | 99.31 | 2.41 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,449 Cr | 293.8 | 5.02 | 16.66% | 15.65% |
| Biocon Ltd. | ₹68,799 Cr | 537.28 | 2.02 | 1.14% | 2.3% |
| Concord Drugs Limited(this company) | ₹98 Cr | 92.51 | 2.01 | 2.17% | 1.35% |
AI analysis
AI-generated · google/gemini-2.5-flashConcord Drugs Limited operates with a market capitalisation of Rs 90 Cr. The company reported a revenue of Rs 45.26 Cr and an EPS of 0.8. The latest available shareholding data from March 2026 shows promoter holding at 54.392% and public holding at 45.608%.
Positives
- +The company reported a high profit margin of 134.6%.
- +Return on equity (ROE) is 217.5%.
- +Promoter holding of 54.392% as of March 2026 indicates significant control.
- +The debt-to-equity ratio is 0.54.
Negatives
- −The Return on Capital Employed (ROCE) is 5.1178%, which is relatively low.
- −The Price-to-Earnings (PE) ratio is 85.31, which is high.
- −Domestic Institutional Investors (DII) holding is 0% as of March 2026.
- −Foreign Institutional Investors (FII) holding is 0% as of March 2026.
Financial performance
For the fiscal year ending March 2025, Concord Drugs Limited reported a revenue of Rs 45.2591 Cr and a net profit of Rs 0.3362 Cr. More recently, in the quarter ending March 2026, the company recorded a revenue of Rs 37.9 Cr and a net profit of Rs 0.53 Cr. The company's highest quarterly revenue since December 2024 was Rs 37.9 Cr in March 2026, and its highest net profit was Rs 0.53 Cr in the same period.
Profitability & returns
The company's profitability is indicated by a profit margin of 134.6%. Return on capital employed (ROCE) stands at 5.1178%. The return on equity (ROE) is 217.5%, based on the latest available annual figures. The price-to-earnings (PE) ratio is 85.31.
Balance sheet
Concord Drugs Limited has a book value of Rs 36.82 per share. The debt-to-equity ratio is 0.54, suggesting a moderate level of debt relative to equity. There is no listed dividend yield.
Ownership & pledges
As of March 2026, the promoter holding in Concord Drugs Limited is 54.392%, while the public holds 45.608%. There are no reported pledged promoter shares.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.